- Home
- GOSS vs EMD Comparison
GOSS vs EMD Comparison
Compare GOSS & EMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- EMD
- Stock Information
- Founded
- GOSS 2015
- EMD 2003
- Country
- GOSS United States
- EMD United States
- Employees
- GOSS N/A
- EMD N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- EMD Finance/Investors Services
- Sector
- GOSS Health Care
- EMD Finance
- Exchange
- GOSS Nasdaq
- EMD Nasdaq
- Market Cap
- GOSS 585.9M
- EMD 592.3M
- IPO Year
- GOSS 2019
- EMD N/A
- Fundamental
- Price
- GOSS $2.41
- EMD $10.37
- Analyst Decision
- GOSS Strong Buy
- EMD
- Analyst Count
- GOSS 6
- EMD 0
- Target Price
- GOSS $8.60
- EMD N/A
- AVG Volume (30 Days)
- GOSS 3.7M
- EMD 248.5K
- Earning Date
- GOSS 11-06-2025
- EMD 01-01-0001
- Dividend Yield
- GOSS N/A
- EMD 10.25%
- EPS Growth
- GOSS N/A
- EMD N/A
- EPS
- GOSS N/A
- EMD N/A
- Revenue
- GOSS $40,237,000.00
- EMD N/A
- Revenue This Year
- GOSS N/A
- EMD N/A
- Revenue Next Year
- GOSS $34.10
- EMD N/A
- P/E Ratio
- GOSS N/A
- EMD N/A
- Revenue Growth
- GOSS N/A
- EMD N/A
- 52 Week Low
- GOSS $0.66
- EMD $7.85
- 52 Week High
- GOSS $3.60
- EMD $9.55
- Technical
- Relative Strength Index (RSI)
- GOSS 44.51
- EMD 52.52
- Support Level
- GOSS $2.25
- EMD $10.12
- Resistance Level
- GOSS $2.61
- EMD $10.42
- Average True Range (ATR)
- GOSS 0.18
- EMD 0.12
- MACD
- GOSS -0.05
- EMD -0.01
- Stochastic Oscillator
- GOSS 24.58
- EMD 61.33
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management, and long term investment company. The primary investment objective of the company is to seek high current income and the secondary objective is to seek capital appreciation.